Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.

Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON

Gut1 Mar 1998Cited by 180 (Europe PMC)

PMID9577356PMCIDPMC1727020DOI10.1136/gut.42.3.442PepBankPUB-09577356

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In advanced hepatocellular carcinoma, median survival was 13 months with octreotide versus four months without treatment (p = 0.002).
In plain wordsIn advanced liver cancer, median survival was 13 months with octreotide versus four months without treatment.
Peptide
Octreotide
Outcome
IncreaseMedian survival
Study
n = 58
Comparator
No treatment
Outcome group
Mortality · Cancer
Studied dose
250 micrograms twice daily · subcutaneousAs given in this study (human).
Measurements
Median survival
13 months
octreotide
Median survival
4 months
no treatment
Log rank P value
0.002 P
octreotide versus no treatment
Source sentences
Summary
Treated patients had an increased median survival (13 months versus four months, p = 0.002, log rank test) and an increased cumulative survival rate at six and 12 months (75% versus 37%, and 56% versus 13% respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty eight patients with advanced hepatocellular carcinoma were randomised to receive either subcutaneous octreotide 250 micrograms twice daily, or no treatment.
Report a problemFND-0957735601
02HumanRandomized controlled trialEfficacy outcome
In advanced hepatocellular carcinoma, six-month survival was 75% with octreotide versus 37% without treatment.
In plain wordsIn advanced liver cancer, six-month survival was 75% with octreotide versus 37% without treatment.
Peptide
Octreotide
Outcome
IncreaseSix-month cumulative survival
Study
n = 58
Comparator
No treatment
Outcome group
Mortality · Cancer
Studied dose
250 micrograms twice daily · subcutaneousAs given in this study (human).
Measurements
Cumulative survival rate at six months
75%
octreotide
Cumulative survival rate at six months
37%
no treatment
Source sentences
Summary
Treated patients had an increased median survival (13 months versus four months, p = 0.002, log rank test) and an increased cumulative survival rate at six and 12 months (75% versus 37%, and 56% versus 13% respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty eight patients with advanced hepatocellular carcinoma were randomised to receive either subcutaneous octreotide 250 micrograms twice daily, or no treatment.
Report a problemFND-0957735602
03HumanRandomized controlled trialEfficacy outcome
In advanced hepatocellular carcinoma, twelve-month survival was 56% with octreotide versus 13% without treatment.
In plain wordsIn advanced liver cancer, twelve-month survival was 56% with octreotide versus 13% without treatment.
Peptide
Octreotide
Outcome
IncreaseTwelve-month cumulative survival
Study
n = 58
Comparator
No treatment
Outcome group
Mortality · Cancer
Studied dose
250 micrograms twice daily · subcutaneousAs given in this study (human).
Measurements
Cumulative survival rate at twelve months
56%
octreotide
Cumulative survival rate at twelve months
13%
no treatment
Source sentences
Summary
Treated patients had an increased median survival (13 months versus four months, p = 0.002, log rank test) and an increased cumulative survival rate at six and 12 months (75% versus 37%, and 56% versus 13% respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty eight patients with advanced hepatocellular carcinoma were randomised to receive either subcutaneous octreotide 250 micrograms twice daily, or no treatment.
Report a problemFND-0957735603
04HumanRandomized controlled trialEfficacy outcome
In advanced hepatocellular carcinoma, octreotide treatment had a lower mortality hazard of 0.383 in multivariable analysis versus no treatment.
In plain wordsIn advanced liver cancer, adjusted mortality hazard was lower with octreotide than without treatment.
Peptide
Octreotide
Outcome
DecreaseAdjusted mortality hazard
Study
n = 58
Comparator
No treatment
Outcome group
Mortality · Cancer
Studied dose
250 micrograms twice daily · subcutaneousAs given in this study (human).
Measurements
Adjusted hazard, treated versus untreated
0.383 ratio
multivariate Cox analysis
Source sentences
Summary
Treated patients clearly had a lower hazard (0.383) in the multivariate analysis.
2 context sentences(design, population, supporting numbers)
Summary · context
When a multivariable Cox's proportional hazards model was fitted, variables associated with increased survival were: treatment administration, absence of cirrhosis, increased serum albumin, and small tumours.
Summary · context
Fifty eight patients with advanced hepatocellular carcinoma were randomised to receive either subcutaneous octreotide 250 micrograms twice daily, or no treatment.
Report a problemFND-0957735605
05HumanNon-randomized trialEfficacy outcome
In advanced hepatocellular carcinoma, octreotide significantly reduced alpha fetoprotein levels at six months.
In plain wordsIn advanced liver cancer, alpha fetoprotein declined significantly after octreotide at six months.
Peptide
Octreotide
Outcome
DecreaseAlpha fetoprotein at six months
Study
n: not reported in source
Outcome group
Cancer biomarkers and prognosis · Cancer
Studied dose
250 micrograms twice daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Octreotide administration significantly reduced alpha fetoprotein levels at six months.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty eight patients with advanced hepatocellular carcinoma were randomised to receive either subcutaneous octreotide 250 micrograms twice daily, or no treatment.
Report a problemFND-0957735604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.